Download the app
App StorePlay Store
Beige
Login
← All tags

biocon

Biocon arm wins Health Canada approval for micafungin injection for deadly fungal infections

Biocon arm wins Health Canada approval for micafungin injection for deadly fungal infections

Biocon Pharma Ltd’s arm has received Health Canada approval for micafungin for injection, aimed at serious fungal infections in both adults and children. The treatment will be used for conditions such as candidemia and esophageal candidiasis, and the approval extends to prophylaxis for stem cell transplant patients. The decision adds a key new offering to Biocon’s portfolio.

Summarised by Beize from a story on The Economic Times on 11 May 2026
Kiran Mazumdar Shaw hands Biocon reins to niece Claire and targets semaglutide push from FY28

Kiran Mazumdar Shaw hands Biocon reins to niece Claire and targets semaglutide push from FY28

Biocon’s Executive Chairperson Kiran Mazumdar-Shaw has mapped a five-year succession plan, naming her niece Claire Mazumdar as successor. The company expects a strong FY27 launch calendar, especially in the second half, driven by its “diabesity” franchise. It also reports significant debt reduction and will channel more operational cash flow toward further deleveraging as it targets a semaglutide push from FY28.

Summarised by Beize from a story on The Economic Times on 11 May 2026

Your news, in seconds

App StorePlay Store
Biocon turns to margins and capacity use after heavy global expansion investments

Biocon turns to margins and capacity use after heavy global expansion investments

Biocon says it is moving from an expansion phase to a focus on capacity utilization, margin expansion, and stronger returns. After major investments to build global capabilities, the company reported 13% revenue growth for FY26, but net profit fell significantly. Biocon is also aiming for sustainable profitable growth while exploring in-licensing for its biosimilars portfolio.

Summarised by Beize from a story on The Economic Times on 8 May 2026
Biocon Q4 profit plunges 63 percent but core business grows

Biocon Q4 profit plunges 63 percent but core business grows

Biocon’s fourth-quarter net profit fell 63% year-on-year, driven by exceptional one-off charges that weighed on the numbers. Despite the shock, the company’s core businesses expanded, supported by the integration of its biosimilars and generics operations. The firm said it will focus on improving profitability and delivering long-term value, recommending a final dividend of Rs 0.50.

Summarised by Beize from a story on The Economic Times on 8 May 2026
Kiran Mazumdar Shaw picks niece Claire as Biocon successor in carefully staged leadership handover

Kiran Mazumdar Shaw picks niece Claire as Biocon successor in carefully staged leadership handover

Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as her successor at Biocon, launching a gradual leadership transition. The founder, who built the biotech company from a garage into a global player, will remain involved while Claire—positioned as a more science-driven leader—takes on increasing responsibility during the handover period.

Summarised by Beize from a story on The Economic Times on 5 May 2026
Biocon names niece Claire Mazumdar as successor after Kiran Mazumdar Shaw exit report

Biocon names niece Claire Mazumdar as successor after Kiran Mazumdar Shaw exit report

Biocon founder Kiran Mazumdar-Shaw has reportedly named her niece, Claire Mazumdar, as the company’s successor. Claire, founder and CEO of Bicara Therapeutics, brings advanced qualifications and prior industry experience. The announcement also comes amid broader structural and leadership changes across Biocon group firms as it pushes biosimilars and deeper artificial intelligence integration.

Summarised by Beize from a story on The Economic Times on 5 May 2026

Never miss a story

App StorePlay Store
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play